Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 59,263 Shares of Stock

MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) CEO John David Hansen sold 59,263 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $0.92, for a total transaction of $54,521.96. Following the transaction, the chief executive officer now directly owns 536,730 shares in the company, valued at $493,791.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

John David Hansen also recently made the following trade(s):

  • On Friday, January 12th, John David Hansen sold 18,582 shares of MabVax Therapeutics stock. The shares were sold at an average price of $0.96, for a total transaction of $17,838.72.
  • On Wednesday, January 10th, John David Hansen sold 110,093 shares of MabVax Therapeutics stock. The shares were sold at an average price of $0.96, for a total transaction of $105,689.28.

MabVax Therapeutics Holdings, Inc. (NASDAQ MBVX) traded down $0.02 during trading on Thursday, hitting $0.87. 267,682 shares of the company’s stock were exchanged, compared to its average volume of 309,694. MabVax Therapeutics Holdings, Inc. has a 12-month low of $0.43 and a 12-month high of $3.57. The company has a market capitalization of $20.45, a price-to-earnings ratio of -0.25 and a beta of 1.52. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.54 and a quick ratio of 0.54.

MabVax Therapeutics (NASDAQ:MBVX) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.54) earnings per share for the quarter. sell-side analysts forecast that MabVax Therapeutics Holdings, Inc. will post -3.01 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in MabVax Therapeutics stock. Cambridge Investment Research Advisors Inc. acquired a new stake in MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned approximately 12.33% of MabVax Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 12.87% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at

MabVax Therapeutics Company Profile

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Insider Buying and Selling by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit